Status:
COMPLETED
A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults
Lead Sponsor:
Pfizer
Conditions:
Pharyngitis
Tonsillitis
Eligibility:
All Genders
13+ years
Phase:
PHASE3
Brief Summary
To determine if a single 2.0-g dose of azithromycin SR is at least as effective as a 3-day course of azithromycin (500 mg once daily for 3 days) when used to treat adolescents and adults with strep th...
Eligibility Criteria
Inclusion
- Patients with evidence of acute group A beta-hemolytic streptococcus (GABHS) pharyngitis/tonsillitis and a positive rapid antigen detection test or positive culture of the pharynx or tonsils for GABHS
Exclusion
- Patients were excluded if they had treatment with any systemic antibiotic within the previous 7 days, a history of rheumatic fever, a peritonsillar abcess, or were known carriers of GABHS.
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2004
Estimated Enrollment :
598 Patients enrolled
Trial Details
Trial ID
NCT00644293
Start Date
January 1 2003
End Date
April 1 2004
Last Update
June 8 2011
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Clearwater, Florida, United States, 33761
2
Pfizer Investigational Site
Boise, Idaho, United States, 83651
3
Pfizer Investigational Site
Boise, Idaho, United States, 83703
4
Pfizer Investigational Site
Boise, Idaho, United States, 83704